within Pharmacolibrary.Drugs.ATC.A;

model A03AE03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 21 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,
    adminCount     = 1,
    Vd             = 0.13,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Cilansetron is a selective serotonin 5-HT3 receptor antagonist that was developed for the treatment of irritable bowel syndrome (IBS), particularly for diarrhea-predominant IBS. The drug showed promise in clinical trials, especially for male patients, but it was never approved for widespread use and is not marketed today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a typical healthy adult based on class similarity with other 5-HT3 antagonists (such as ondansetron). No direct published PK study found for cilansetron.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A03AE03;
